Skip to main content

Throne Jason's Form 4 filing

IDEAYA Biosciences, Inc. (IDYA) · filed Sep 6, 2023

Accession no.
0001610717-23-000258
Filed
Sep 6, 2023
Trade date
Sep 1-5, 2023
Filing delay
5 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $115.2K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Throne JasonCIK 0001790865Officer (Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 1, 2023Common StockMOption exerciseAcquired+2,100$12.86+$27,0062,100Direct
Sep 1, 2023Common StockSSaleDisposed−2,100$30.03F2−$63,0630Direct
Sep 5, 2023Common StockMOption exerciseAcquired+1,737$12.86+$22,337.821,737Direct
Sep 5, 2023Common StockSSaleDisposed−1,737$30.03F3−$52,162.110Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 1, 2023Common StockMOption exerciseDisposed−2,100$0.00$056,650Direct
Sep 5, 2023Common StockMOption exerciseDisposed−1,737$0.00$054,913Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades in prices ranging from $30.00 to $30.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades in prices ranging from $30.00 to $30.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)